Parkinson's disease is a disorder of the central nervous system (brain and spinal cord). Carbidopa and levodopa combination is also used to treat parkinsonism caused by encephalitis, or parkinsonism caused by carbon monoxide or manganese poisoning.

Carbidopa/levodopa is commonly used to treat Parkinson’s disease, a condition that affects the part of your brain that controls your movements. It may also be used to treat conditions with...

KINSON contains the active ingredients levodopa and carbidopa. KINSON is used to treat some of the symptoms of Parkinson's disease. For more information, see Section 1. Why am I using KINSON?...

2023年4月5日 · KINSON contains the active ingredients levodopa and carbidopa. KINSON is used to is used to treat some of the symptoms of Parkinson's disease. This is a disease of the nervous system that mainly affects body movement.

2025年1月7日 · Levodopa and carbidopa is used for the treatment of Parkinson's disease, post-encephalitic Parkinsonism, and symptomatic Parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

KINSON is a combination of levodopa, the metabolic precursor of dopamine, and carbidopa, an aromatic amino acid decarboxylase inhibitor, for the treatment of Parkinson’s disease and syndrome. Each tablet contains 100 mg of levodopa and 25 mg of carbidopa (as monohydrate) as the active ingredients.

The combination of levodopa and carbidopa is used to treat the symptoms of Parkinson's disease and Parkinson's-like symptoms that may develop after encephalitis (swelling of the brain) or injury to the nervous system caused by carbon monoxide poisoning or manganese poisoning.

It is sold under several brand names, including Sinemet (Merck Sharp & Dohme Limited), Pharmacopa, Atamet, Apo-Levocarb, Duodopa, Kinson, and Pharmacopa, among others. Extended-release formulations are sold as Rytary and Sinemet-CR.

2025年1月7日 · Carbidopa is a dopa decarboxylase inhibitor used in combination with levodopa for the symptomatic treatment of idiopathic Parkinson disease and other conditions associated with parkinsonian symptoms.

Carbidopa is a peripheral aromatic amino acid decarboxylase inhibitor. It prevents metabolism of levodopa to dopamine in the peripheral circulation, ensuring that a higher proportion of the dose reaches the brain, where dopamine exerts its therapeutic effects.